Bell KJ - Search Results

1

Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.

Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, Howard K, Armstrong B, Thompson JF, Irwig L. Turner RM, et al. Among authors: bell kj. J Clin Oncol. 2011 Dec 10;29(35):4641-6. doi: 10.1200/JCO.2010.34.2956. Epub 2011 Nov 7. J Clin Oncol. 2011. PMID: 22067399

2

Use of randomised trials to decide when to monitor response to new treatment.

Bell KJ, Irwig L, Craig JC, Macaskill P. Bell KJ, et al. BMJ. 2008 Feb 16;336(7640):361-5. doi: 10.1136/bmj.39476.623611.25. BMJ. 2008. PMID: 18276713 Free PMC article.

3

Mixed models showed no need for initial response monitoring after starting antihypertensive therapy.

Bell KJ, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Bell KJ, et al. J Clin Epidemiol. 2009 Jun;62(6):650-9. doi: 10.1016/j.jclinepi.2008.07.018. Epub 2008 Dec 23. J Clin Epidemiol. 2009. PMID: 19108988 Clinical Trial.

4

Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.

Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC. Bell KJ, et al. BMJ. 2009 Jun 23;338:b2266. doi: 10.1136/bmj.b2266. BMJ. 2009. PMID: 19549996 Free PMC article. Clinical Trial.

5

Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers.

Bell KJ, Irwig L, March LM, Hayen A, Macaskill P, Craig JC. Bell KJ, et al. Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):99-105. doi: 10.1002/pds.1868. Pharmacoepidemiol Drug Saf. 2010. PMID: 19802829

6

The value of routine BMD monitoring after starting bisphosphonate treatment.

Bell KJ, Hayen A, Irwig L, Macaskill P, Craig JC, Ensrud KE, Bauer DC. Bell KJ, et al. J Bone Miner Res. 2010 Jan;25(1):173-4. doi: 10.1359/jbmr.091111. J Bone Miner Res. 2010. PMID: 19929431 Free article. No abstract available.

7

Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials.

Bell KJ, Hayen A, Macaskill P, Craig JC, Neal BC, Fox KM, Remme WJ, Asselbergs FW, van Gilst WH, Macmahon S, Remuzzi G, Ruggenenti P, Teo KK, Irwig L. Bell KJ, et al. Hypertension. 2010 Sep;56(3):533-9. doi: 10.1161/HYPERTENSIONAHA.110.152421. Epub 2010 Jul 12. Hypertension. 2010. PMID: 20625081

8

Monitoring adherence to medication by measuring change in blood pressure.

Hayen A, Bell K, Glasziou P, Neal B, Irwig L. Hayen A, et al. Hypertension. 2010 Oct;56(4):612-6. doi: 10.1161/HYPERTENSIONAHA.110.153817. Epub 2010 Aug 9. Hypertension. 2010. PMID: 20696980 Clinical Trial.

9

Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data.

Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P. Bell KJ, et al. BMJ. 2011 Jan 21;342:d12. doi: 10.1136/bmj.d12. BMJ. 2011. PMID: 21257657 Clinical Trial.

10

Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk.

Bell K, Hayen A, McGeechan K, Neal B, Irwig L. Bell K, et al. Eur J Prev Cardiol. 2012 Dec;19(6):1474-85. doi: 10.1177/1741826711424494. Epub 2011 Sep 26. Eur J Prev Cardiol. 2012. PMID: 21947629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters